At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,071 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)
In Brief
An observational study for Atrial Fibrillation. Completed, enrolled 1,071 participants across 41 sites in 14 countries.
Detailed Summary
Prospective, multi-center, single-arm, non-interventional and open-label registry. The purpose of the registry is to document use of Phased Radio Frequency Ablation (RFA) (hereafter "Phased RFA") System in a real world patient population with atrial fibrillation (AF) and evaluate its performance. Gold AF will enroll a minimum of 1,000 patients who undergo Phased RFA in approximately 38 sites in Western, Central Europe, Israel and South Korea.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesFrance, Georgia, Germany, Greece, Hungary, Israel, Italy, Netherlands, Poland, Portugal, South Korea, Spain, Switzerland, United Kingdom
CollaboratorsIHF GmbH - Institut für Herzinfarktforschung
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMar 2015
First PostedMay 2015
Primary CompletionNov 2018
Study CompletionMay 2019
TodayJul 2026
First PostedMay 5, 2015
Enrollment StartMar 1, 2015
Primary CompletionNov 20, 2018
Study CompletionMay 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 11.2 years ago